On Monday, Unum Group (NYSE:UNM)’s shares declined -0.56% to $35.82.
Unum Group (UNM) continues to experience sturdy sales and premium income enhance in addition to stable risk performance across core business segments and the closed block. These in turn assisted the company to outperform the Zacks Consensus Estimate in the first quarter.
With respect to the earnings surprise trend, the Zacks Rank #3 (Hold) accident and health insurer delivered a positive surprise in three of the last four quarters, with an average beat of 1.17%.
Over the past few years, the company’s conservative pricing and reservation practices have contributed to its overall profitability. Unum estimates 2015 operating earnings to grow 2–5% from the 2014 level.
In addition, Unum Group anticipates solid persistency and sales improvement in existing client relationships to continue driving sales higher in Unum U.S.
Unum Group, together with its auxiliaries, provides group and individual disability insurance products in the United States and the United Kingdom. The company operates through three segments: Unum US, Unum UK, and Colonial Life. It provides group long-term and short-term disability, group life, accidental death and dismemberment, individual disability, supplemental and voluntary products, and group and individual long-term care insurance products, in addition to accident, sickness and disability products, life products, and cancer and critical illness products.
Marriott International Inc (NASDAQ:MAR)’s shares dropped -0.65% to $74.31.
Marriott International Inc (MAR) the world’s favorite travel company, and Universal Music Group (UMG), the global music leader, have created a first-of-its-kind global marketing partnership that will comprise exclusive performances by established and emerging recording artists, branded video series, social content, music downloads, ticket offers and more. The partnership joins Marriott International’s 19 brands, counting The Ritz-Carlton, EDITION, JW Marriott, Renaissance and Marriott Hotels, with illustrious UMG music labels such as Capitol Music Group, Def Jam Recordings, Interscope Geffen A&M, Island Records, Republic Records and UMG Nashville.
Marriott and UMG are setting out to engage a new generation of experience-seekers, travelers and music fans to deliver unique #WithTheBand experiences. Starting this summer, the partnership will premiere live performances for hotel guests at select properties across Marriott International’s portfolio of brands around the globe. On June 30, 2015, the St. Pancras Renaissance London Hotel will feature a live performance by pop sensation and ‘The Voice Australia’ judge, Jessie J, kicking off a series of exclusive, on-property performances on five different continents.
Marriott International, Inc. operates, franchises, and licenses hotels and timeshare properties worldwide. It operates through three segments: North American Full-Service, North American Limited-Service, and International. The company also licenses the development, operation, marketing, sale, and administration of vacation ownership and related products under the Marriott Vacation Club, Grand Residences by Marriott, The Ritz-Carlton Destination Club, and The Ritz-Carlton Residences brands to the Marriott Vacations Worldwide Corporation.
At the end of Monday’s trade, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)‘s shares surged 2.38% to $140.10.
BioMarin Pharmaceutical Inc. (BMRN) declared the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for drisapersen for the treatment of Duchenne Muscular Dystrophy amenable to exon 51 skipping. Validation of the MAA confirms that the submission is complete and starts the EMA’s standard review process. Day 120 questions will be received on 22 October 2015, leading to a potential CHMP opinion in the first half of 2016 and a European Commission Decision by the third quarter of 2016.
Drisapersen is an investigational antisense oligonucleotide drug candidate for the treatment of the largest subset of Duchenne muscular dystrophy (DMD) amenable to single exon skipping. Drisapersen induces the skipping of dystrophin exon 51, potentially providing a therapeutic benefit to DMD patients for whom skipping of exon 51 restores the proper dystrophin reading frame, corresponding to about 13% of DMD patients.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products comprise Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease.
Medivation Inc (NASDAQ:MDVN), ended its Monday’s trading session with 1.34% gain, and closed at $113.56.
Medivation, Inc. ( MDVN) eclared that it has issued a notice of redemption to redeem on July 24, 2015 all of its outstanding 2.625% Convertible Notes due 2017 (the “Notes”). As of June 18, 2015, $167.7 million of the Notes was outstanding. The last stated sale price of Medivation’s common stock was $116.62 per share on June 18, 2015.
The notice of redemption provides that the Notes called for redemption would be redeemed at a stated redemption price equal to 100% of the aggregate principal amount of such Notes, plus accrued and unpaid interest to (but not counting) the redemption date.+
Holders may convert the Notes at any time prior to the close of business on July 22, 2015 at a conversion rate of 19.5172 shares of Medivation’s common stock per $1,000 principal amount of Notes (which is equivalent to a conversion price of about $51.24 per share) with a related Conversion Period (as defined in the Indenture for the Notes) of June 23, 2015 through July 21, 2015. Holders who want to convert their Notes must satisfy the requirements set forth in Article 5 of the Indenture for the Notes. In the event that holders elect to convert their Notes in connection with the redemption, the Company will satisfy its conversion obligations to holders by paying cash equal to the principal amount of the Notes and any conversion obligation in excess of the principal amount will be paid in shares of Medivation’s common stock.
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
